Ensign Peak Advisors Inc Raises Stake in Axon Enterprise, Inc. (NASDAQ:AXON)

Ensign Peak Advisors Inc lifted its holdings in shares of Axon Enterprise, Inc. (NASDAQ:AXON - Free Report) by 11.5% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 32,965 shares of the biotechnology company's stock after acquiring an additional 3,402 shares during the quarter. Ensign Peak Advisors Inc's holdings in Axon Enterprise were worth $19,592,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of AXON. New Wave Wealth Advisors LLC purchased a new stake in Axon Enterprise in the fourth quarter worth $40,000. Y.D. More Investments Ltd bought a new position in Axon Enterprise during the fourth quarter worth about $45,000. Stonebridge Financial Group LLC purchased a new position in shares of Axon Enterprise in the fourth quarter worth about $53,000. GPS Wealth Strategies Group LLC raised its stake in shares of Axon Enterprise by 74.1% during the 4th quarter. GPS Wealth Strategies Group LLC now owns 94 shares of the biotechnology company's stock valued at $56,000 after purchasing an additional 40 shares during the period. Finally, Berbice Capital Management LLC purchased a new stake in Axon Enterprise during the 4th quarter worth about $59,000. 79.08% of the stock is currently owned by institutional investors.

Axon Enterprise Stock Performance

Shares of Axon Enterprise stock traded down $0.14 during trading on Thursday, hitting $728.39. 569,924 shares of the company's stock traded hands, compared to its average volume of 762,776. The business has a 50-day simple moving average of $576.22 and a 200-day simple moving average of $589.48. Axon Enterprise, Inc. has a 1 year low of $273.52 and a 1 year high of $732.22. The company has a debt-to-equity ratio of 0.32, a current ratio of 2.96 and a quick ratio of 2.63. The stock has a market capitalization of $56.71 billion, a P/E ratio of 188.21, a PEG ratio of 5.17 and a beta of 1.24.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The biotechnology company reported $1.41 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.34 by $0.07. Axon Enterprise had a net margin of 15.37% and a return on equity of 7.50%. The firm had revenue of $603.63 million during the quarter, compared to analysts' expectations of $585.67 million. During the same period in the prior year, the company posted $1.15 earnings per share. The company's revenue for the quarter was up 31.3% compared to the same quarter last year. As a group, analysts forecast that Axon Enterprise, Inc. will post 5.8 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. The Goldman Sachs Group increased their price target on shares of Axon Enterprise from $730.00 to $830.00 and gave the stock a "buy" rating in a report on Wednesday. Needham & Company LLC boosted their price target on shares of Axon Enterprise from $600.00 to $750.00 and gave the stock a "buy" rating in a research note on Thursday, May 8th. Craig Hallum lowered Axon Enterprise from a "buy" rating to a "cautious" rating in a research note on Monday, March 10th. Northcoast Research downgraded Axon Enterprise from a "buy" rating to a "neutral" rating in a report on Wednesday, February 19th. Finally, Barclays increased their price objective on Axon Enterprise from $726.00 to $735.00 and gave the stock an "overweight" rating in a report on Friday, May 9th. One analyst has rated the stock with a sell rating, one has given a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $652.73.

Insider Buying and Selling at Axon Enterprise

In other Axon Enterprise news, CEO Patrick W. Smith sold 10,000 shares of the company's stock in a transaction on Monday, April 21st. The stock was sold at an average price of $540.99, for a total value of $5,409,900.00. Following the transaction, the chief executive officer now owns 3,063,982 shares of the company's stock, valued at $1,657,583,622.18. This represents a 0.33% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Matthew R. Mcbrady sold 400 shares of the stock in a transaction that occurred on Wednesday, May 14th. The stock was sold at an average price of $718.40, for a total value of $287,360.00. Following the completion of the transaction, the director now directly owns 3,492 shares in the company, valued at approximately $2,508,652.80. This trade represents a 10.28% decrease in their position. The disclosure for this sale can be found here. Insiders sold 23,764 shares of company stock worth $14,856,635 in the last quarter. 4.40% of the stock is owned by corporate insiders.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.